[{"orgOrder":0,"company":"Polpharma","sponsor":"Pikralida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Marimastat","moa":"MMP","graph1":"Neurology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Polpharma \/ Pikralida","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Pikralida"},{"orgOrder":0,"company":"Polpharma","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"CDK8","graph1":"Oncology","graph2":"Phase II","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Polpharma \/ Ryvu Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Polpharma \/ Ryvu Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Polpharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : RVU120

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Ryvu Therapeutics

                          Deal Size : $1.9 million

                          Deal Type : Agreement

                          Details : The agreement will support the clinical development of RVU120, a miscellaneous product targeting CDK8, to address Acute Myeloid Leukemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 06, 2023

                          Lead Product(s) : RVU120

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Ryvu Therapeutics

                          Deal Size : $1.9 million

                          Deal Type : Agreement

                          Polpharma CB

                          02

                          Lead Product(s) : Marimastat

                          Therapeutic Area : Neurology

                          Study Phase : Preclinical

                          Sponsor : Pikralida

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : The partnership with Marimastat aims to advance epilepsy treatment by targeting MMP.

                          Product Name : PKL-021

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 19, 2022

                          Lead Product(s) : Marimastat

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Pikralida

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Polpharma CB